Name | Thomas Hospital |
---|---|
Type | Acute Care Hospital |
Location | 750 Morphy Avenue, Fairhope, Alabama |
Ownership | Voluntary non-profit - Private |
Emergency Services | Yes |
Medicare ID (CCN) | 010100 |
NPI Number | 1447303227 |
Organization Name | GULF HEALTH HOSPITALS, INC |
Doing Business As | THOMAS HOSPITAL |
Address | 750 Morphy Avenue, Fairhope, AL 36532 |
Hospital Type | General Acute Care Hospital |
Phone Number | 251-928-2375 |
News Archive
Infection control practices for detecting and treating patients infected with emerging multidrug-resistant gram-negative bacteria (MDR-GNB) vary significantly between hospitals.
Today's headlines include reports about how the congressional health debate might proceed in the wake of last weekend's violence and more details on New York's Medicaid challenges.
The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).
Overactive bladder symptom complex is a symptom complex, the pivotal symptom of which is urgency, which is a compelling desire to pass urine, which is difficult to defer.
A newly identified "metabolic signature" can evaluate an individual's adherence and metabolic response to the Mediterranean diet and help predict future risk of developing cardiovascular disease (CVD), according to new research led by Harvard T.H. Chan School of Public Health with collaborators from the Broad Institute of MIT and Harvard and Spain.
› Verified 3 days ago
NPI Number | 1831415827 |
Organization Name | INFIRMARY THERAPY SERVICES |
Doing Business As | THOMAS HOSPITAL |
Address | 212 Hospital Dr, Suite B, Fairhope, AL 36532 |
Hospital Type | Rehabilitation Hospital - Children |
Phone Number | 251-279-1640 |
News Archive
Infection control practices for detecting and treating patients infected with emerging multidrug-resistant gram-negative bacteria (MDR-GNB) vary significantly between hospitals.
Today's headlines include reports about how the congressional health debate might proceed in the wake of last weekend's violence and more details on New York's Medicaid challenges.
The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).
Overactive bladder symptom complex is a symptom complex, the pivotal symptom of which is urgency, which is a compelling desire to pass urine, which is difficult to defer.
A newly identified "metabolic signature" can evaluate an individual's adherence and metabolic response to the Mediterranean diet and help predict future risk of developing cardiovascular disease (CVD), according to new research led by Harvard T.H. Chan School of Public Health with collaborators from the Broad Institute of MIT and Harvard and Spain.
› Verified 3 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
Infection control practices for detecting and treating patients infected with emerging multidrug-resistant gram-negative bacteria (MDR-GNB) vary significantly between hospitals.
Today's headlines include reports about how the congressional health debate might proceed in the wake of last weekend's violence and more details on New York's Medicaid challenges.
The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).
Overactive bladder symptom complex is a symptom complex, the pivotal symptom of which is urgency, which is a compelling desire to pass urine, which is difficult to defer.
A newly identified "metabolic signature" can evaluate an individual's adherence and metabolic response to the Mediterranean diet and help predict future risk of developing cardiovascular disease (CVD), according to new research led by Harvard T.H. Chan School of Public Health with collaborators from the Broad Institute of MIT and Harvard and Spain.
› Verified 3 days ago
Thomas Hospital Acute Care Hospital Location: 750 Morphy Avenue, Fairhope, Alabama 36532 Phone: (251) 928-2375 |